The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.
 
Ian Chau
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Merck Serono; Sanofi
Research Funding - Merck Serono (Inst); Novartis (Inst); Roche Pharma AG (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Markus Peck-Radosavljevic
Honoraria - Bayer; Boehringer Ingelheim; Lilly; Novartis; ONXEO
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Lilly; ONXEO
Speakers' Bureau - Bayer; Lilly
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly
 
Christophe Borg
No Relationships to Disclose
 
Peter Malfertheiner
Speakers' Bureau - Aptalis; AstraZeneca; Takeda
 
Jean Francois Seitz
Honoraria - Lilly
Consulting or Advisory Role - Lilly
Research Funding - Lilly (Inst)
 
Joon Oh Park
Research Funding - GlaxoSmithKline; Sanofi
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Chia-Jui Yen
No Relationships to Disclose
 
Masatoshi Kudo
No Relationships to Disclose
 
Ronnie Tung-Ping Poon
No Relationships to Disclose
 
Davide Pastorelli
No Relationships to Disclose
 
Jean-Frédéric Blanc
Consulting or Advisory Role - Lilly/ImClone
 
Hyun Cheol Chung
Consulting or Advisory Role - Celltrion; Lilly
 
Ari David Baron
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Lilly
 
Takuji Okusaka
Honoraria - Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Fujifilm; Lilly Japan; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Amgen; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly Japan; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca; Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Nippon Boehringer Ingelheim; Novartis; OncoTherapy Science; Ono Pharmaceutical; Otsuka; Pfizer; Sceti Medical Labo; Shizuoka; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Zhanglin Lin Cui
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Allicia C. Girvan
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Paolo Abada
Employment - Lilly
 
Ling Yang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Andrew X. Zhu
Consulting or Advisory Role - Eisai